1 unknown. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Unknown 1 |
Follow High-Risk: new trials by email Literature Review of High-Risk trials Research Report on High-Risk
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable Tislelizumab, Nab-paclitaxel - High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 63 | 2020-12-27 | 2021-10-29 |
130-nm albumin-bound paclitaxel (1) · tislelizumab (1)
Tianjin Medical University Second Hospital (1)
China (1)